Active, not recruitingPhase 3NCT04504825
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Studying AL amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Principal Investigator
- Scott Swenson, MDAlexion, AstraZeneca Rare Disease
- Intervention
- CAEL-101(drug)
- Enrollment
- 125 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2025
Study locations (17)
- Research Site, Duarte, California, United States
- Research Site, Palo Alto, California, United States
- Research Site, San Francisco, California, United States
- Research Site, Weston, Florida, United States
- Research Site, Indianapolis, Indiana, United States
- Research Site, New Orleans, Louisiana, United States
- Research Site, Boston, Massachusetts, United States
- Research Site, Detroit, Michigan, United States
- Research Site, Rochester, Minnesota, United States
- Research Site, St Louis, Missouri, United States
- Research Site, New York, New York, United States
- Research Site, Rochester, New York, United States
- Research Site, Winston-Salem, North Carolina, United States
- Research Site, Cleveland, Ohio, United States
- Research Site, Columbus, Ohio, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04504825 on ClinicalTrials.govOther trials for AL amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06963216A Study Investigating Coagadex in the Treatment AFXD Associated With AL AmyloidosisKedrion S.p.A.
- RECRUITINGPHASE3NCT07388602A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)Sinocelltech Ltd.
- RECRUITINGPHASE1, PHASE2NCT07266116Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis PatientsShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- RECRUITINGNCT07448935One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMSFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGNCT07448779Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and TreatmentFondazione IRCCS Policlinico San Matteo di Pavia
- RECRUITINGPHASE2NCT07110844Teclistamab-Daratumumab in AL AmyloidosisSuzanne Lentzsch, MD
- RECRUITINGPHASE1NCT07250269Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL AmyloidosisGracell Biotechnologies (Shanghai) Co., Ltd.
- RECRUITINGNCT07172243BE.Amycon Biobank & Data Registry UZ LeuvenUniversitaire Ziekenhuizen KU Leuven